When Michaela Thompson heard that a new immunotherapy may be the cure for her son’s cancer, she was skeptical. “It sounded a little too good to be true,” she recalled. At the time, eight-year-old Lucas had been battling leukemia for nearly three years. And by the time doctors presented chimeric antigen receptor T cell therapy as a treatment option, he had had two relapses from prior chemotherapy and a bone marrow transplant.

Read the rest of the story in Drug Discovery News or here.

Image credit: Anna Tarazevich via Pexels